GLUT

STF-31 is an inhibitor of glucose transporter 1 (GLUT1, IC50 = 1 muM),

WZB117 is an inhibitor of Glucose Transporter 1 (GLUT1). It inhibited cell proliferation in lung cancer A549 cells and breast cancer MCF7 cells with an IC50 of approximately 10 uM.

BAY-876 is a potent and Selective GLUT1 Inhibitor. BAY-876 showed good metabolic stability in vitro and high oral bioavailability in vivo.

D927 (GLUT4 activator 1, DS11252927) is a potent glucose transporter type 4 (GLUT4) translocation activator with an EC50 of 0.14 μM.

Lavendustin B is an inhibitor of HIV-1 integrase interaction with LEDGF/p75 with an IC50 of 94.07 μM. Lavendustin B is an ATP-competitive GLUT1 inhibitor with a Ki of 15 ?M. Lavendustin B is also a weak inhibitor of tyrosine kinases.

AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3, also known as GPR41), with an IC₅₀ of 117 nM. It demonstrates anti-inflammatory, antitumor, and antidiabetic activities. AR420626 improves neurogenic diarrhea by modulating neural pathways mediated by nicotinic acetylcholine receptors (nAChRs). In cancer models, it suppresses the growth of HepG2 xenografts and inhibits hepatoma cell proliferation through apoptosis induction. Additionally, AR420626 mitigates allergic asthma and eczema and enhances glucose uptake by activating FFAR3-mediated Ca²⁺ signaling, offering potential therapeutic benefits in metabolic disorders such as diabetes.

GLUT4-IN-2 is a selective inhibitor of the glucose transporter GLUT4, exhibiting IC50 values of 6.8 µM for GLUT4 and 11.4 µM for GLUT1. This compound has been shown to induce cell apoptosis and arrest the cell cycle at the G0/G1 phase, highlighting its potential as an anticancer agent. GLUT4-IN-2 is suitable for research applications aimed at understanding glucose metabolism and evaluating therapeutic strategies in cancer biology.